MA
Insider
Matt Abernethy
Chief Financial OfficerMatt Abernethy (Chief Financial Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $363K of NBIX (2,311 sh × $157.20, as filed), executed Sep 14.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$363K
shares × price, as filed
Last traded
Sep 14
Filed Sep 15
Median ADV $194.2M across their filed names
Open performance→Volume by month
Buys $0
Sells $974K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
NBIX
Neurocrine Biosciences, Inc.
NBIX · 0 buys · 4 sells
4 filings
Recent filings
NBIXSALE
Neurocrine Biosciences, Inc.
View filing →
$363K2,311 sh × $157.20
Exec Sep 14
Filed Sep 15 · 5:02 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $299K
2,558 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $116K
980 sh × $118.27
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $196K
1,283 sh × $152.87
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET